Skip to main content
Vicore Pharma Holding logo

Vicore Pharma Holding — Investor Relations & Filings

Ticker · VICO ISIN · SE0007577895 LEI · 549300KTNBPTZLF01130 ST Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2026-05-11 Major Shareholding Noti…
Country SE Sweden
Listing ST VICO

About Vicore Pharma Holding

https://vicorepharma.com/

Vicore Pharma Holding is a clinical-stage pharmaceutical company developing a new class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), with disease-modifying potential. The company's research focuses on diseases where the AT2 receptor has a central role in stopping and reversing pathology. Its lead candidate, buloxibutid (C21), is a first-in-class, orally available small molecule ATRAG in clinical development for idiopathic pulmonary fibrosis (IPF). Vicore is also developing Almee™, a digital therapeutic based on cognitive behavioral therapy for the psychological impact of pulmonary fibrosis, which has received FDA Breakthrough Device Designation. The company utilizes its expertise in ATRAG chemistry and biology to build a pipeline primarily focused on respiratory diseases.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2026
Major Shareholding Notification Classification · 95% confidence The document is a disclosure of a change in shareholding by The Capital Group Companies, Inc. in Vicore Pharma Holding AB, providing pre-transaction and post-transaction share counts and voting rights in compliance with the Swedish Financial Supervisory Authority’s major shareholding notification rules (FITA Ch. 4). It is a classic Major Shareholding Notification rather than an earnings release or regulatory filing. Therefore, it matches category MRQ.
2026-05-11 English
Announcement from the Annual General Meeting of Vicore Pharma Holding AB (publ)
Regulatory Filings
2026-05-06 English
Kommuniké från årsstämma i Vicore Pharma Holding AB (publ)
Regulatory Filings
2026-05-06 Swedish
KALLELSE TILL ÅRSSTÄMMA I VICORE PHARMA HOLDING AB (PUBL)
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice (“kallelse”) convening the Annual General Meeting, including agenda items, participation instructions, proxy forms, and voting procedures. This constitutes materials sent to shareholders to inform and solicit votes for the meeting rather than the meeting results or a published report. Therefore, it is classified as a Proxy Solicitation & Information Statement (PSI).
2026-04-01 Swedish
NOTICE OF ANNUAL GENERAL MEETING IN VICORE PHARMA HOLDING AB (PUBL)
Proxy Solicitation & Information Statement Classification · 94% confidence The document is a detailed notice and information statement for the Annual General Meeting, including the meeting date, venue, record date, registration and advance voting procedures, agenda items, and proposed resolutions (proxy form instructions, voting by mail). It is not the AGM presentation itself but rather the proxy solicitation/information statement sent to shareholders to inform and request votes. Therefore, it best fits the Proxy Solicitation & Information Statement category.
2026-04-01 English
Annual Report (ESEF) 2025
Annual Report (ESEF) Classification · 100% confidence FY 2025
2026-03-26 Swedish

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.